The US Food and Drug Administration has accepted a New Drug Application for the investigational drug UGN-102 (mitomycin) from UroGen Pharma as an intravesical therapy. UGN-102 could become the first FDA-approved therapy for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The mechanism of action for UGN-102 involves a sustained-released hydrogel formulation of mitomycin that allows for longer exposure of bladder tissue to the drug, potentially sparing patients from surgical intervention. ...
Non-Muscle Invasive Urothelial Carcinoma
Advertisement
Latest News
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Results of SunRISe-1 provide support for TAR-200 monotherapy in patients with BCG-unresponsive high-risk NMIBC.
Dr. Daneshmand shares his thoughts on alternative intravesical therapies in NMIBC and how they compare for efficacy, safety.
If approved, mitomycin is anticipated to become the first FDA-approved treatment for LG-IR-NMIBC.
Dr. Sia Daneshmand highlights latest advancements in bladder preservation strategies for patients with NMIBC.
BCG is ineffective in 30% to 77% of patients, and many experience disease recurrence within 5 years.
Advertisement
Urothelial Carcinoma Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Conference Coverage
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Dr. Choueiri outlines the importance of experts putting their heads together to decide on how to approach gray areas.
Advertisement
Section Editor
Sia Daneshmand, MDEditor | Professor of Urology and Medicine (Oncology) at the University of Southern California
Advertisement
Latest News
In part two of this roundtable, multidisciplinary approaches to managing MIBC are discussed.
The first segment of this roundtable series focuses on the latest developments in MIBC treatment, including the NIAGARA trial
In the final part of this roundtable series, the panelists share their thoughts on the most anticipated upcoming trials.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.